New heart valve device tested in humans for first time

NCT ID NCT05182307

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new device called the DurAVR™ THV System, a replacement heart valve placed through a small tube in an artery, for people with severe aortic stenosis (a narrowed heart valve). The trial involves 150 participants and aims to see if the device is safe and works well. It is the first time this valve is being tested in humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DurAVR™ THV System (a replacement heart valve implanted via a catheter)
What this could lead to
If successful, this could offer a new, less invasive treatment option for people with severe aortic stenosis, potentially improving heart function and survival.
What could go wrong
This is a very early, first-in-human study with only 150 participants. The device may not work as expected, and risks include bleeding, stroke, or heart attack. Long-term benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE CALCIFICATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tbilisi Heart and Vascular Clinic Ltd

    Tbilisi, Georgia

More trials for these conditions

Other studies related to the condition(s) this trial covers.